Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug782 | Clinical Trial Matching Wiki | 0.71 |
drug4001 | photobiomodulation and photodynamic therapy Wiki | 0.71 |
drug623 | COVID-19 convalescent plasma Wiki | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
D016889 | Endometrial Neoplasms NIH | 0.71 |
D007414 | Intestinal Neoplasms NIH | 0.71 |
D013274 | Stomach Neoplasms NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D012878 | Skin Neoplasms NIH | 0.71 |
D005770 | Gastrointestinal Neoplasms NIH | 0.71 |
D009423 | Nervous System Neoplasms NIH | 0.71 |
D007680 | Kidney Neoplasms NIH | 0.71 |
D016543 | Central Nervous System Neoplasms NIH | 0.71 |
D005909 | Glioblastoma NIH | 0.71 |
D008113 | Liver Neoplasms NIH | 0.71 |
D007822 | Laryngeal Neoplasms NIH | 0.71 |
D013736 | Testicular Neoplasms NIH | 0.71 |
D002292 | Carcinoma, Renal Cell NIH | 0.50 |
D002583 | Uterine Cervical Neoplasms NIH | 0.50 |
D012004 | Rectal Neoplasms NIH | 0.50 |
D018281 | Cholangiocarcinoma NIH | 0.50 |
D018358 | Neuroendocrine Tumors NIH | 0.50 |
D010190 | Pancreatic Neoplasms NIH | 0.41 |
D006258 | Head and Neck Neoplasms NIH | 0.41 |
D002277 | Carcinoma NIH | 0.35 |
D003110 | Colonic Neoplasms NIH | 0.35 |
D001943 | Breast Neoplasms NIH | 0.32 |
D008175 | Lung Neoplasms NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002896 | Neoplasm of the liver HPO | 0.71 |
HP:0008069 | Neoplasm of the skin HPO | 0.71 |
HP:0012114 | Endometrial carcinoma HPO | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100006 | Neoplasm of the central nervous system HPO | 0.71 |
HP:0010788 | Testicular neoplasm HPO | 0.71 |
HP:0009726 | Renal neoplasm HPO | 0.71 |
HP:0012174 | Glioblastoma multiforme HPO | 0.71 |
HP:0100751 | Esophageal neoplasm HPO | 0.71 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.71 |
HP:0006753 | Neoplasm of the stomach HPO | 0.71 |
HP:0100605 | Neoplasm of the larynx HPO | 0.71 |
HP:0005584 | Renal cell carcinoma HPO | 0.50 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.50 |
HP:0100743 | Neoplasm of the rectum HPO | 0.50 |
HP:0030153 | Cholangiocarcinoma HPO | 0.50 |
HP:0030079 | Cervix cancer HPO | 0.50 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.41 |
HP:0012288 | Neoplasm of head and neck HPO | 0.41 |
HP:0030731 | Carcinoma HPO | 0.35 |
HP:0003003 | Colon cancer HPO | 0.35 |
HP:0003002 | Breast carcinoma HPO | 0.32 |
HP:0100526 | Neoplasm of the lung HPO | 0.29 |
Navigate: Correlations HPO
There are 2 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearA multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a consequence of COVID-19?
Description: The primary endpoint is to show if in Italy the number of cancer mentioned above, was diagnosed in a more advanced stage (i.e. > I stage, Metastatic disease) in 2020 compared to 2019 as a consequence of COVID-19 pandemic condition.
Measure: Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019. Time: From January 2019 to December 2020Description: To show any difference in the rate of cancer related neo-adjuvant therapy in 2020 compared to 2019;
Measure: Rate of neo-adjuvant therapy in 2020 compared to 2019 Time: From January 2019 to December 2020Description: To show any difference in the rate of cancer related palliative procedures/ bridge therapy in 2020 compared to 2019, before starting with standard treatment;
Measure: Rate of palliative procedure in 2020 compared to 2019 Time: From January 2019 to December 2020Description: To show any difference of patients unable to performer cancer related preoperative chemo or radiotherapy in 2020 compared to 2019 due to scarce performance status or for symptomatic disease;
Measure: Rate of preoperative chemo or radiotherapy in 2020 compared to 2019 for metastatic disease. Time: From January 2019 to December 2020Description: Rate of patients unable to performer cancer related adjuvant therapy in 2020 compared to 2019 due to scarce performance status
Measure: Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019 Time: From January 2019 to December 2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports